Treatment and prevention of osteoporosis.
Osteoporosis is recognized as a major health threat. The number of patients will certainly grow with the aging of the population. While preventive strategies, such as calcium, vitamin D, exercise and reduced risk factors may diminish the impact of menopause and age-regulated bone loss, many patients will become candidates for pharmacologic therapy. A variety of options are available, including HRT, bisphosphonates, SERMs, calcitonin, strontium ranelate, teriparatid. New forms of treatment are appearing on the horizon, such as monoclonal antibodies, nitrates, beta-blockers and Cathepsin K inhibitors.
Blahos
Jaroslav
J
Endocrine Unit and Osteocentre, Central Military Hospital, Prague, Czech Republic. blahos@cls.cz
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D015444:Exercise; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D010024:Osteoporosis / Q000517:prevention & control / Q000628:therapy*; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control / Q000628:therapy; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D019379:Teriparatide / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D015507:Drugs, Investigational; D009942:Organometallic Compounds; D020845:Selective Estrogen Receptor Modulators; D013876:Thiophenes; C081587:strontium ranelate; D019379:Teriparatide; D014807:Vitamin D; D002116:Calcitonin